REV-ERB clock proteins emerge as Alzheimer’s disease drug targets

Deep inside the brain’s immune cells, a pair of molecular clock proteins may hold the key to a radically different way of treating Alzheimer’s disease. A new narrative review published in the British Journal of Biomedical Science argues that REV-ERBα and REV-ERBβ, two heme-sensitive nuclear receptors that sit at the heart of the circadian clock, are far more than timekeepers. They are nodal integrators of circadian timing, lipid metabolism, and innate immunity, and their dysfunction appears to be a recurring feature of the Alzheimer’s brain. The review, led by Fahmida Shabnam and Kristine Griffett of Auburn University together with Meenakshi Singh and Rajesh Amin, synthesizes genetic, transcriptomic, and pharmacological evidence to position these receptors as promising yet complex therapeutic targets.

Alzheimer’s disease remains the most prevalent cause of dementia worldwide, characterized clinically by progressive memory and executive deficits and pathologically by amyloid-β plaques, tau neurofibrillary tangles, synaptic loss, and chronic neuroinflammation. Current pharmacological interventions confer at best modest symptomatic benefit and have limited impact on long-term disease progression. Mounting evidence indicates that circadian rhythm disruption is both highly prevalent in patients and may actively exacerbate amyloid deposition, tauopathy, and neuroimmune dysfunction. Core clock components regulate sleep-wake cycles, energy metabolism, redox homeostasis, and immune signaling, and disturbances in clock-controlled neuroimmune circuits in microglia and astrocytes are increasingly recognized as central contributors to sustained neuroinflammation and synaptic vulnerability in the aging and diseased brain.

REV-ERBα (NR1D1) and REV-ERBβ (NR1D2) are atypical members of the nuclear receptor superfamily. Structurally, they diverge from classical ligand-activated receptors by lacking the carboxy-terminal activation function-2 helix within their ligand-binding domain, a motif normally required for coactivator recruitment and transcriptional activation. As a consequence, they behave predominantly as constitutive transcriptional repressors, often competing with the transcriptionally activating ROR nuclear receptors at shared RORE sites. Ligand engagement within the hydrophobic pocket of the ligand-binding domain, most notably by endogenous heme or synthetic agonists, stabilizes a conformation that enhances high-affinity binding to the nuclear receptor corepressor NCoR1/2 and enables assembly of a multi-protein repression complex containing histone deacetylase 3. Recruitment of NCoR-HDAC3 results in targeted deacetylation of histone tails, chromatin compaction, and durable silencing of REV-ERB target enhancers and promoters. Within the core clockwork, REV-ERBs oppose the activity of the BMAL1-CLOCK complex, repressing Bmal1 transcription and shaping 24-hour oscillations in gene expression.

Beyond their canonical clock roles, REV-ERB complexes regulate extensive transcriptional networks controlling inflammatory signaling, intermediary metabolism, and the core clock machinery. In immune cells, REV-ERBα directly binds regulatory elements near Il-1β, Il-6, and Tnfα, limiting their inducible expression and constraining NF-κB-driven inflammatory programs. In peripheral macrophages, NR1D1 directly binds the Nlrp3 promoter to constrain NLRP3 inflammasome activity and the maturation of interleukin-1β and interleukin-18, positioning the REV-ERBs as gatekeepers of innate immune activation. In metabolic tissues, REV-ERBs occupy enhancers of genes such as Pgc1α and Srebp1, rhythmically recruiting HDAC3 to coordinate mitochondrial biogenesis, fatty acid oxidation, and lipogenesis with circadian nutrient availability. The review frames this convergence as molecular integration of immune-metabolic timing, translating oscillations in heme and redox state into coordinated changes in chromatin accessibility across diverse cell types.

Transcriptomic and proteomic analyses reveal significantly reduced levels of REV-ERBα in Alzheimer’s disease brains, particularly within vulnerable regions such as the frontal cortex, hippocampus, and suprachiasmatic nucleus. In both human postmortem tissue and AD mouse models, these reductions coincide with disrupted clock gene rhythmicity and impaired coupling between the SCN and downstream oscillators. Single-cell and single-nucleus RNA-seq datasets from human AD cortex and hippocampus now provide cellular resolution, demonstrating a consistent downregulation of NR1D1 transcripts in disease-associated microglia and subsets of reactive astrocytes relative to homeostatic counterparts in control brains. Clusters with reduced NR1D1 show enrichment of pro-inflammatory gene modules and complement and chemokine signatures, implicating loss of REV-ERBα repression as a key step in the transition from physiological to pathological glial states. The authors caution, however, that direct measurements of NR1D1 or NR1D2 proteins in CSF or blood remain limited, and most evidence linking REV-ERB pathways to human disease derives from transcriptomic datasets and postmortem tissue analyses rather than validated fluid biomarkers.

The microglial story is the most mechanistically developed. In global Nr1d1 knockout mice, loss of this repression leads to spontaneous hippocampal microgliosis and secondary astrogliosis, accompanied by enhanced NF-κB p65 nuclear accumulation and upregulation of pro-inflammatory cytokines and complement factors including Il-1β, Tnfα, and C1q. Beyond cytokines, Nr1d1 deletion disrupts the circadian control of complement gene expression, producing exaggerated diurnal swings and an overall elevation of chemokines such as Ccl2 and Cxcl10, complement components C3 and C4b, and inflammasome-associated transcripts like Nlrp3 and Casp1. These changes collectively favor excessive synaptic tagging and microglial phagocytosis. Strikingly, depletion of microglia in these knockout mice normalizes many of the behavioral and cognitive abnormalities and attenuates neuroinflammatory signatures, demonstrating that hyperactivated microglia are the principal effectors of the neuropathology that emerges when REV-ERBα signaling is lost.

Tauopathy models provide further evidence that microglial REV-ERBα links inflammatory tone, lipid metabolism, and protein aggregate clearance. In PS19 mice expressing mutant human P301S tau, microglia-specific Nr1d1 deletion exacerbates tau aggregation and neurofibrillary tangle burden. Notably, these effects are sex-specific, occurring only in male mice, while female mice show no exacerbation of tau pathology. In affected males, loss of REV-ERBα increases inflammatory cytokine expression and drives accumulation of lipid droplets within microglia. This clogged metabolic state impairs their phagocytic capacity for pathological tau species, and pharmacologic or genetic blockade of lipid droplet formation partially restores tau uptake. The review also distinguishes experimentally validated functions from extrapolated models: direct evidence supports regulation of NF-κB signaling, complement expression, microglial synaptic phagocytosis, lipid droplet accumulation, and tau pathology, whereas links to broader inflammasome networks, oxidative stress pathways, and certain aspects of amyloid pathology remain largely mechanistic inferences.

Astrocytic REV-ERBα exerts context-dependent effects that diverge sharply from the microglial picture. In the astrocyte compartment, absence of this receptor induces an increase in bulk brain and astrocytic NAD+ levels via an NFIL3-CD38 signaling axis, where REV-ERBα deficiency leads to derepression of NFIL3, which subsequently limits CD38-dependent NAD+ consumption and preserves intracellular NAD+ pools. In P301S tauopathy models, this astrocytic REV-ERBα deficiency attenuates tau aggregation, neuroinflammation, and neuronal loss, indicating that reduced astrocytic REV-ERBα activity can paradoxically confer neuroprotection by enhancing NAD+-dependent stress resilience. Yet in primary astrocyte cultures and human iPSC-derived astrocytes, reduction of NR1D1 drives a robust pro-inflammatory shift characterized by upregulation of IL-6, NOS2, and NF-κB reporter activity alongside a neurotoxic phenotype that compromises cocultured neuron survival. Astrocytic REV-ERBα thus functions as a dual-purpose regulator, simultaneously restraining inflammatory gene expression and tuning redox and NAD+ metabolism, and the net outcome appears to depend on disease stage, injury context, and the balance between immune repression and metabolic control.

Pharmacological activation confers broad neuroprotective effects across multiple experimental paradigms. The first-generation synthetic agonist GSK4112 established proof-of-concept that small molecules can ligand-dependently enhance REV-ERB-NCoR interactions and repress canonical target genes such as Bmal1, but its low potency and poor metabolic stability limited its use largely to in vitro studies. Second-generation benzimidazole derivatives SR9009 and SR9011 exhibited greater bioavailability, CNS penetration, and in vivo efficacy. In APP/PS1 mice, systemic administration of these agonists reduces microgliosis and astrogliosis, attenuates NF-κB-dependent inflammatory gene programs, and restores performance in hippocampal-dependent memory tasks. In microglia and macrophages, these agonists attenuate pro-inflammatory cytokine production, suppress NLRP3 inflammasome activation, and shift cellular metabolism toward a less oxidative, lower-ATP state. Nonetheless, SR9009 and SR9011 display relatively short plasma half-lives, off-target effects at higher concentrations, and modest receptor affinity, which together constrain their translational potential. The competitive antagonist SR8278 tells a bidirectional story: short-term treatment enhances Aβ clearance by upregulating phagocytic receptors including TREM2 and P2Y12 and boosting microglial chemotaxis, but chronic or high-dose exposure has been associated with exacerbated astrogliosis and increased pro-inflammatory gene expression. More recently, the high-affinity pan-agonist STL1267 has emerged as a next-generation tool compound with submicromolar binding to REV-ERBα, enhanced metabolic stability, and superior in vivo exposure. Structural studies reveal that STL1267 occupies a deep hydrophobic cavity within the REV-ERBα ligand-binding domain, and structure-activity relationship analyses have identified a cluster of residues, particularly phenylalanine 484, 488, and 497 together with leucine 498, as critical determinants of agonist binding, forming a hydrophobic microenvironment that cradles the ligand and stabilizes the agonist-bound conformation favoring productive NCoR/HDAC3 recruitment.

The rhythmic nature of REV-ERB signaling adds another layer of complexity and opportunity. Circadian disruption happens early in Alzheimer’s disease, and core clock components like REV-ERBα directly affect neuroinflammation and neuronal vulnerability. Preclinical studies already provide proof-of-principle for chronotherapeutic REV-ERB modulation: in rodent models, restricting dosing of REV-ERB ligands or other anti-inflammatory agents to specific circadian phases improves restoration of clock gene rhythms in hippocampus and cortex, enhances diurnal variation in glial activation markers, and more effectively reduces cytokine levels and complement activation than phase-mismatched schedules. Time-restricted administration also appears to better preserve sleep-wake architecture and cognitive performance. Long-term systemic activation of REV-ERBs may produce adverse consequences because these receptors regulate lipid metabolism, glucose homeostasis, skeletal muscle energetics, immune responses, and cardiovascular physiology, a challenge particularly relevant for elderly AD patients who frequently exhibit multimorbidity and altered sleep-wake rhythms. The review argues that therapeutic success will rely on cell-type-selective modulation, stage-specific strategies, and precise calibration rather than a simple push for maximal receptor activation. Future research should prioritize cell-type and time-resolved mapping of REV-ERB chromatin occupancy in human and experimental AD, development of brain-penetrant and isoform-selective next-generation ligands, integration of REV-ERB-targeted treatments with existing AD therapies such as anti-amyloid antibodies or NLRP3 inhibitors, and tracking of circadian biomarkers like sleep-wake metrics and melatonin rhythms alongside standard neurodegeneration markers in early clinical studies. Emerging ATX(N)-based biomarker frameworks increasingly recognize inflammatory, vascular, metabolic, and synaptic pathways as clinically relevant components of AD biology beyond amyloid and tau alone, and future studies integrating NR1D1/NR1D2 expression, circadian biomarkers, and blood-based inflammatory markers may help determine whether REV-ERB pathway dysfunction can serve as a clinically informative biomarker of disease progression. The evidence positions REV-ERBs as modular, homeostatic sensors at the intersection of circadian timing, metabolic flux, and neuroimmune function, active determinants of whether glial responses remain protective or shift into chronic, neurotoxic inflammation in the Alzheimer’s brain.

Subject of Research: REV-ERBs as regulators of circadian rhythm, neuroinflammation, and glial lipid homeostasis in Alzheimer’s disease. A narrative review

Article Title: REV-ERBs as regulators of circadian rhythm, neuroinflammation, and glial lipid homeostasis in Alzheimer’s disease. A narrative review

Article References: Shabnam, F., Singh, M., Amin, R., & Griffett, K. (2026). REV-ERBs as regulators of circadian rhythm, neuroinflammation, and glial lipid homeostasis in Alzheimer’s disease. A narrative review. British Journal of Biomedical Science, 83, Article 16121. https://doi.org/10.3389/bjbs.2026.16121

Image Credits: AI Generated

DOI: 10.3389/bjbs.2026.16121

Keywords: REV-ERBs, regulators, circadian, rhythm, neuroinflammation, glial, lipid, homeostasis, Alzheimer, disease, narrative, review